Best of ASH Annual Meeting & Exposition | Conference

Amitkumar Mehta, MD, on Compelling Data From ASH in the Treatment of Lymphoma
February 10, 2022

Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.

Michael R. Bishop, MD, on Impactful Research in Lymphoma Presented at 2021 ASH
February 03, 2022

Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.

Yael Cohen, MD, on Promising Therapeutics in the Heavily Pretreated Myeloma Space
January 19, 2022

Yael Cohen, MD, sat down with CancerNetwork® to spotlight a number of promising treatments that are under investigation for patients with heavily-pretreated multiple myeloma.

Ginzburg Discusses Most Interesting Presentations From ASH 2021
January 11, 2022

At the 2021 ASH Annual Meeting, Yelena Ginzburg, MD, spoke about presentations she found most groundbreaking.

Jakubowiak Talks Daratumumab Quadruplet Therapy and the GRIFFIN Study at 2021 ASH
January 07, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, talks about daratumumab-based quadruplet therapies being evaluated in clinical trials and the potential impact they’ll have on the multiple myeloma treatment landscape.

Matthew S. Davids, MD, Discusses Important Abstracts Presented at ASH 2021
December 26, 2021

Matthew S. Davids, MD, spoke about which abstracts presented at ASH 2021 he felt were most important.

Lindsey Roeker, MD, Discusses Which Data From ASH 2021 Have the Biggest Potential to Impact Care
December 23, 2021

Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.

Fonseca Highlights Data Regarding CAR T-cell Therapy and Bi-Specific Antibodies for Myeloma at 2021 ASH
December 15, 2021

When asked about abstracts he thinks have the greatest potential to impact the standard of care in myeloma, Rafael Fonseca, MD, looked to emerging cellular therapies, specifically ciltacabtagene autoleucel for the treatment of heavily pretreated disease.

Jeffrey Wolf, MD, on Implications of Findings from Multiple Myeloma Study Presented at ASH
December 27, 2020

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

Guido Lancman, MD, on the Study Design of IVIG in Patients with Multiple Myeloma Receiving Daratumumab
December 26, 2020

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.